Daiichi Sankyo has pushed back the reporting of its annual results, saying it needs more time to finalize the numbers.
The Japanese company had intended to unveil its financials for its fiscal year that ended …
Regeneron’s Otarmeni is the first gene therapy for congenital hearing loss to be cleared by the FDA, and will be made available for free in
Patients’ confidence in their ability to find answers about health questions and make informed decisions has plummeted in the past year, according to an Edelman
Regeneron has won the first ever FDA approval for a gene therapy to treat a rare type of inherited hearing loss, and the company plans
The US Justice Department has issued an order moving medical marijuana to Schedule III, removing some barriers to access for patients and researchers.
Tempero Bio, a drug developer that had big ambitions to shake up the treatment of substance use disorders, is winding down operations, Endpoints News has
Daiichi Sankyo has pushed back the reporting of its annual results, saying it needs more time to finalize the numbers.
The Japanese company had intended to unveil its financials for its fiscal year that ended …